The act would prohibit pharmacy benefit managers and pharmacies from being under common ownership, potentially creating a more equitable and competitive healthcare landscape.
Clinical Assistant Professor, Department of Medicine, Tulane University School of Medicine, New Orleans; Rheumatologist, The Rheumatology Group, Metairie, Louisiana
Reforming or regulating these oligopolies — UnitedHealth Group, CVS, and Cigna — including their PBMs and all of their pharmacies has proved extremely challenging over the years. As we try to nibble around the edges of many of the harmful behaviors of PBMs, they always seem to find a way around the intent of the legislation.
It will prevent conflict-of-interest behavior by preventing PBMs from directing patients to their affiliated pharmacies, which many argue inflate drug costs. This bill will also inject much-needed transparency into the realm of drug pricing and reimbursement for pharmacists. It would lead to increased fairness in the pharmacy market, allowing independent pharmacists to compete on a level playing field.
Healthcare Reform Drug Costs Drug Cost Medication Costs Drug Price Drug Pricing Medication Price Medication Pricing Practice Management Revenue Pre-Exposure HIV Prophylaxis HIV Prep Preexposure HIV Prophylaxis Biologic Therapy Biologics Trump And Healthcare Trump And Healthcare Reform Healthcare Reform Under Trump Trump Health Insurance Louisiana Generics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
House passes Laken Riley Act in first legislative act of new CongressPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
House Passes Laken Riley Act, Trump's First Legislative ActThe House of Representatives passed the Laken Riley Act on Wednesday, sending it to President Donald Trump for his signature. The bill, named after a nursing student murdered by an illegal immigrant, strengthens immigration enforcement by mandating the detention of illegal aliens charged with serious crimes. It also requires ICE to notify victims' families when encountering such individuals.
Read more »
UK Regulator to Investigate Apple and Google for Potential Browser and Mobile Ecosystem MonopoliesThe UK's Competition and Markets Authority (CMA) is launching investigations into Apple and Google over concerns about their dominance in smartphone browsers and mobile ecosystems. The CMA suspects they may be hindering innovation and holding a duopoly, which could lead to penalties similar to those imposed on Apple in the EU under the Digital Markets Act.
Read more »
Success in Osteoporosis Research Can Lead to Underrecruitment ChallengesA research team in Australia encountered a surprising problem: their successful tracking of osteoporosis patients through medical records actually hindered their ability to recruit participants for a clinical trial. The team, led by Christopher White, PhD, had developed a comprehensive database of over 30,000 patients with osteoporosis and their fracture risks. However, they underestimated the severity of vertebral fractures in some patients, leading to underrecruitment. This experience prompted White to collaborate with other centers facing similar challenges, leveraging AI and AES coding to identify patients at risk for osteoporotic fractures more effectively.
Read more »
Rheumatoid Arthritis Linked to Increased Risk of Heart Failure with Preserved Ejection FractionA study using data from the Mass General Brigham Biobank found that patients with rheumatoid arthritis (RA) have a significantly higher risk of developing heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). The study, which followed patients for a median of 10.3 years, identified that RA patients had a 79% increased risk of HF compared to those without the condition. HFpEF was the predominant HF subtype in both groups, and RA patients experienced a higher incidence of HFpEF. The authors suggest that chronic inflammation associated with RA may contribute to this increased risk.
Read more »
Xanomeline/Trospium Shows Cognitive Improvement in Schizophrenia PatientsA new study found that xanomeline/trospium chloride, a novel M1/M4 muscarinic receptor agonist, significantly improved cognitive function in patients with acute schizophrenia and cognitive impairment. The analysis combined data from two 5-week inpatient phase 3 trials involving 357 adult patients. Patients receiving xanomeline/trospium showed the largest improvement in verbal recognition memory, with additional benefits observed for sustained attention and executive functioning. The treatment effect was most pronounced in patients with more severe baseline cognitive impairment.
Read more »